IRB Barcelona researchers uncover a new strategy to tackle obesity by activating brown fat

(Press-News.org) Barcelona, 4 September 2025 – Is it possible to treat obesity without reducing food intake? A new study co-led by Dr. Antonio Zorzano and Dr. Manuela Sánchez-Feutrie at the Institute for Research in Biomedicine (IRB Barcelona) suggests that this might be a possibility, at least in animal models. Published in Nature Communications, the research identifies a key role for Neuritin 1, a protein previously linked to the nervous system, which is also produced in brown adipose tissue, where it acts as a powerful driver of energy expenditure and metabolic health.

Unlike current anti-obesity and antidiabetic drugs, such as Ozempic or tirzepatide, which work by suppressing appetite, Neuritin 1 boosts energy burning without affecting food intake. “By increasing the levels of Neuritin 1 specifically in brown fat, we observed that the animals burned more energy, which helped prevent fat accumulation,” explains Dr. Zorzano, who is also a professor at the University of Barcelona and a researcher at CIBERDEM.

This metabolic boost led to significant improvements in several health indicators, including reduced weight gain, improved insulin sensitivity, and lower liver inflammation, even in animals fed high-calorie diets.

 

Neuritin 1: a new player in energy metabolism

Previously described for its role in neuronal plasticity, Neuritin 1 is now shown to have a metabolic function in brown fat, a type of fat specialised in generating heat through a process known as thermogenesis. This process involves burning energy to maintain body temperature, particularly in response to cold. In this context, Neuritin 1 stimulates mitochondrial activity and promotes the expression of thermogenic genes.

To trigger its expression, the researchers used a viral vector that drives Neuritin 1 overexpression exclusively in thermogenic fat cells. The result was a sustained increase in metabolic activity, without affecting food consumption or physical activity in the animals.

“These findings point to Neuritin 1 as a promising therapeutic candidate for treating obesity and its associated conditions, such as type 2 diabetes and fatty liver disease, through a mechanism that differs from current approaches,” highlights Dr. Sánchez-Feutrie.

 

Relevance to human health

Beyond the animal model results, genetic data in humans also show a correlation between Neuritin 1 and susceptibility to obesity, reinforcing the potential relevance of the discovery. The team is currently exploring ways to translate these findings into a future therapeutic strategy.

The study was made possible thanks to the contributions of several IRB Barcelona core facilities, including Bioinformatics and Biostatistics, Functional Genomics, Protein Expression, and Histopathology. It also involved collaborators from international institutions such as the CNRS (France), Karolinska Institutet (Sweden), and the University of Houston (USA).

 

Research disclaimer:
This research is still in its early stages. While the findings are promising, additional studies will be needed before considering potential therapeutic applications in humans.

END